Tocagen Names Lori Kunkel To Board
This article was originally published in Scrip
Tocagen Inc., a clinical-stage immuno-oncology company, has appointed Lori Kunkel to its board of directors. With more than 20 years' experience in oncology and immunology drug development, Kunkel is currently on the board of Loxo Oncology. Prior to this, she was chief medical officer of Pharmacyclics (acquired by AbbVie) and Proteolix Inc (acquired by Onyx Pharmaceuticals). She was also vice-president of clinical development at Xencor, Inc.
Register for our free email digests: